Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 5Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 17Glioblastoma 8Esophageal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Oropharyngeal Neoplasms 7Breast Neoplasms 7Mouth Neoplasms 6Glioma 6Triple Negative Breast Neoplasms 4Lung Neoplasms 4Laryngeal Neoplasms 4Head and Neck Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Sarcoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Neuroblastoma 2Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Medulloblastoma 2Hypopharyngeal Neoplasms 2Ganglioneuroblastoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Cyclophosphamide 29blinatumomab 19Vincristine 16Specimen Handling 13Methotrexate 13Dexamethasone 13fludarabine 12Prednisone 11Cytarabine 11Biopsy 11Doxorubicin 9Asparaginase 9Rituximab 8Mercaptopurine 8Inotuzumab Ozogamicin 8merphos 7Spinal Puncture 7N,N-dicyclohexyl-isoborneol-10-sulfonamide 7Magnetic Resonance Spectroscopy 7venetoclax 6prednylidene 6dexamethasone acetate 6dexamethasone 21-phosphate 6deltacortene 6azathiopurine 6auricularum 6Etoposide 6Daunorubicin 6Calcium Dobesilate 6pegaspargase 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Burkitt Lymphoma × Radiation × Clear all
NCT06124157 2026-06-03

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
222 enrolled
Lymphoid

Burkitt Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡